Uracil Tegafur Tablets

Similar to Tegafur, it gradually transforms into fluorouracil in the body to interfere with and block the synthesis of DNA, RNA and protein. Experimental studies have shown that uracil can block the degradation of Tegafur and specifically increase the concentration of fluorouracil and its active metabolites in tumor tissues. By using different ratios of Tegafur and uracil and measuring the concentration of fluorouracil in animals (B) and tumors (T), it was shown that when the ratio of the two was 1:4, the ratio of fluorouracil concentration in tumors and blood (T/B) was the largest. 4 hours after administration, the concentration of fluorouracil in tumors was the highest, with a T/B ratio of 23, which was much higher than that in other normal tissues such as spleen, lung, brain, muscle, brain marrow, liver, thymus, kidney and testicular tissues. Patients were given 300 mg of fluorouracil and different ratios of uracil, and then surgery was performed. The concentrations of fluorinated uracil in plasma (B), tumors (T) and surrounding normal tissues (N) were compared. It was also shown that when the ratio was 1:4, the T/B and T/N ratios were the largest, 10.0 and 4.1 respectively. The mechanism of action of this product is explained by some people as inhibiting the decomposition of fluorouracil in tumor tissue after adding uracil, because the concentration of fluorouracil is increased accordingly; in addition, fluorouracil is mainly decomposed in the liver and part of the tumor tissue. After adding uracil, only a trace amount of decomposition is found in the tumor tissue, which may also be related to the large number of phosphorylated products of fluorouracil in the tumor. The clinical pharmacology is similar to that of tegafur.

This product is a compound preparation of tegafur and uracil. Each tablet contains 50 mg of tegafur and 0.112 g of uracil.

This product is white tablets.

It is used for digestive tract cancers such as stomach cancer, intestinal cancer, pancreatic cancer, and can also be used for breast cancer and primary liver cancer. Taking the medicine before and after surgery may prevent the recurrence, spread, and metastasis of cancer.

Oral administration, 3 times a mouthful, 2-4 tablets each time or as directed by your doctor.

Mild bone marrow suppression is manifested by leukopenia and thrombocytopenia. Mild gastrointestinal reactions are mainly loss of libido and nausea. Some patients may experience vomiting, diarrhea and abdominal pain, which may disappear after stopping the drug. Other reactions include fatigue, chills, fever, headache, dizziness, ataxia, skin itching, pigmentation, mucositis, etc.

1. Pregnant and lactating women are prohibited from using this product. 2. People who are allergic to this product are prohibited from using this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not for use by pregnant and lactating women. Precautions for the elderly: Not yet clear.

The tegafur contained in this product is alkaline and contains carbonate. Avoid using it with drugs containing calcium or magnesium ions or strong acidity.

Keep in a dark place and sealed. The validity period is tentatively set at two years.

0.162g

24 months

RenHe Hetero Pharmaceuticals Ltd.

• Founded in:

  2014-03-19

• Address:

  No. 20, Jieyi Road, Guandu Biomedicine Industrial Park, Zhongmou County, Zhengzhou City, Henan Province

• Tax NO.:

  914100000947871309

• Registered Funds:

  $40 million

• Website:

  Log in to view

• Email:

  Log in to view